Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.

Détails

ID Serval
serval:BIB_93835B0029BA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.
Périodique
Journal of Clinical Oncology
Auteur⸱e⸱s
Bourhis J., Lapeyre M., Tortochaux J., Rives M., Aghili M., Bourdin S., Lesaunier F., Benassi T., Lemanski C., Geoffrois L., Lusinchi A., Verrelle P., Bardet E., Julieron M., Wibault P., Luboinski M., Benhamou E.
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
24
Numéro
18
Pages
2873-2878
Langue
anglais
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial Publication Status: ppublish
Résumé
PURPOSE: With the aim to increase the dose intensity of radiation therapy (RT), and subsequently the locoregional control rate, a very accelerated RT regimen was compared with conventional RT in a series of patients with head and neck squamous cell carcinoma (HNSCC).
PATIENTS AND METHODS: Between 1994 and 1998, 268 patients with T3 or T4, N0 to N3 HNSCC (staged by 1997 International Union Against Cancer criteria) that was not eligible for surgery were randomly assigned to receive either conventional RT, delivering 70 Gy in 7 weeks to the primary tumor and 35 fractions of 2 Gy over 49 days, or to receive very accelerated RT, delivering 62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days (2 Gy/fraction bid).
RESULTS: The most common tumor site was the oropharynx and most of the patients (70%) had T4 and N1 to N3 tumors in 72% of patients. The main patient and tumor characteristics were well-balanced between the two arms. The median total doses were 63 Gy (accelerated) and 70 Gy (conventional), with a median overall time of 22 days and 48 days, respectively. Acute mucositis was markedly increased in the accelerated-RT arm (P < .001). The locoregional control rate was improved by 24% at 6 years with accelerated RT. In contrast, disease-free survival and overall survival were not significantly different between the two arms. There was no difference in late effects between the two arms.
CONCLUSION: The very accelerated RT regimen was feasible and provided a major benefit in locoregional control but had a modest effect on survival.
Mots-clé
Carcinoma, Squamous Cell/radiotherapy, Dose Fractionation, Head and Neck Neoplasms/radiotherapy, Humans, Survival Analysis
Pubmed
Web of science
Création de la notice
01/12/2014 18:36
Dernière modification de la notice
20/08/2019 15:56
Données d'usage